SNPMiner Trials by Shray Alag


SNPMiner SNPMiner Trials (Home Page)


Report for Mutation G21210A

Developed by Shray Alag, 2020.
SNP Clinical Trial Gene

There are 3 clinical trials

Clinical Trials


1 Aspirin After Six Months or One Year of Oral Anticoagulants for the Prevention of Recurrent Venous Thromboembolism in Patients With Idiopathic Venous Thromboembolism. The WARFASA Study.

To determine whether aspirin is more effective than placebo for the prevention of recurrent symptomatic venous thromboembolism when given for at least two years after the initial 6-12 month of oral anticoagulant therapy in patients with idiopathic venous thromboembolism

NCT00222677 Venous Thromboembolism Deep Venous Thrombosis Pulmonary Embolism Atherosclerosis Drug: aspirin
MeSH: Pulmonary Embolism Thrombosis Atherosclerosis Thromboembolism Embolism Venous Thromboembolism Venous Thrombosis
HPO: Atherosclerosis Deep venous thrombosis Pulmonary embolism Thromboembolism Type IV atherosclerotic lesion Venous thrombosis

Exclusion Criteria: - permanent risk factors for venous thromboembolism: patients known to have antiphospholipid antibodies or lupus anticoagulant (based on local laboratory criteria) or to have homozygous factor V Leiden or homozygous prothrombin G21210A or heterozygous factor V Leiden plus heterozygous prothrombin G21210A or antithrombin III deficiency; patients with active malignancy - temporary risk factors for venous thromboembolism - any recurrence of venous thromboembolism or bleeding episode during the established 6-month period of oral anticoagulant treatment - allergy or intolerance of aspirin - clear indication for aspirin or other anti-platelet therapy (e.g. --- G21210A ---

Exclusion Criteria: - permanent risk factors for venous thromboembolism: patients known to have antiphospholipid antibodies or lupus anticoagulant (based on local laboratory criteria) or to have homozygous factor V Leiden or homozygous prothrombin G21210A or heterozygous factor V Leiden plus heterozygous prothrombin G21210A or antithrombin III deficiency; patients with active malignancy - temporary risk factors for venous thromboembolism - any recurrence of venous thromboembolism or bleeding episode during the established 6-month period of oral anticoagulant treatment - allergy or intolerance of aspirin - clear indication for aspirin or other anti-platelet therapy (e.g. --- G21210A --- --- G21210A ---

Primary Outcomes

Measure: recurrence of VTE and/or VTE related death

Time: at least 24 months per patient

Secondary Outcomes

Measure: recurrent VTE+ death; cardiovascular events, bleeding events, critical ischemia of the lower limbs, mesenteric infarction, all cause mortality and newly diagnosed cancer

Time: at least 24 months per patient

2 An Open-label, Phase II Study of Cyclophosphamide, Lenalidomide and Dexamethasone (CLD) for Previously Treated Patients With AL Amyloidosis

The treatment of light-chain (AL) amyloidosis is directed against the plasma cells that produce the light-chain forming the amyloid deposits. The plasma cells can be killed and their growth can be stopped by drugs used in chemotherapy, such as cyclophosphamide, steroids, such as dexamethasone, and drugs that stimulate the immune system, such as lenalidomide. The present trial studies the efficacy and safety of the combination of cyclophosphamide, lenalidomide and dexamethasone in patients with AL amyloidosis who were previously treated and need further therapy.

NCT00607581 Amyloidosis Drug: cyclophosphamide Drug: lenalidomide Drug: dexamethasone
MeSH: Immunoglobulin Light-chain Amyloidosis Amyloidosis
HPO: Amyloidosis

Prior diagnosis of antiphospholipid antibodies or lupus anticoagulant, factor V Leiden mutation, prothrombin G21210A mutation, antithrombin, protein C or S deficiency. --- G21210A ---

Primary Outcomes

Measure: hematologic response rate

Time: at 3 months

Secondary Outcomes

Measure: organ response rate

Time: at 3 months

Measure: time to response

Time: every 28 days

Measure: time to progression

Time: every 3 months for 3 years

Measure: survival

Time: up to 3 years after treatment discontinuation

Measure: toxicity

Time: continuous during treatment

3 A Phase 3, Prospective, Randomized Clinical Study of VELCADE-Thalidomide-Dexamethasone (VTD) Versus Thalidomide-Dexamethasone (TD) for Previously Untreated Multiple Myeloma (MM) Patients Who Are Candidates to Receive Double Autologous Transplantation

Thalidomide-Dexamethasone (TD) is a standard induction therapy for Multiple Myeloma (MM). The present study is designed to compare TD with VELCADE-Thalidomide-Dexamethasone (VTD) as induction therapy in preparation for, and as consolidation after, melphalan-based double autologous stem cell transplantation for previously untreated patients aged ≤65 years with symptomatic MM. Primary study endpoint is the rate of complete response (CR) plus near-complete response (nCR) to induction treatment. Secondary endpoints include the rate of CR plus nCR to double transplantation and subsequent consolidation therapy, time to progression (TTP), progression-free survival (PFS),overall survival (OS) and toxicity profile of both VTD and TD.

NCT01134484 Multiple Myeloma Drug: Velcade Drug: Thalidomide Drug: Dexamethasone Procedure: Peripheral Blood Stem Cell (PBSC) collection Procedure: First Autologous Transplantation Procedure: Second Autologous Transplantation
MeSH: Multiple Myeloma Neoplasms, Plasma Cell
HPO: Multiple myeloma

- Patient has a previous diagnosis of antiphospholipid antibodies or lupus anticoagulant, factor V Leiden mutation, prothrombin G21210A mutation, antithrombin, protein C or S deficiency. --- G21210A ---

Primary Outcomes

Description: Responses to induction therapy were reported by study investigators and centrally reassessed by study coordinator(s). Criteria are those initially proposed by the European Group for Blood and Marrow Transplantation (EBMT), with the addition of nCR (100% M-protein reduction by electrophoresis, but immunofixation-positive) and very good partial response (VGPR) (at least 90% serum and urine M-protein reduction) categories. Comparisons of response rates between treatment arms are performed using Fisher's exact test.

Measure: Rate of CR+nCR to induction treatment

Time: 63 days after the start day of either TD or VTD as induction therapy

Secondary Outcomes

Description: Responses to autotransplantation(s) and consolidation therapy were reported by study investigators and centrally reassessed by study coordinator(s). Criteria are those initially proposed by the EBMT, with the addition of nCR and VGPR categories. Comparisons of response rates between treatment arms are performed using Fisher's exact test. Comparisons of response rates between treatment arms are performed using Fisher's exact test.

Measure: Rate of CR+nCR to autotransplantation(s) and subsequent consolidation therapy

Time: 90 days after the second autologous transplantation and 70 days after the beginning of either TD or VTD as consolidation therapy

Description: TTP is defined as time from start of induction treatment with either TD or VTD to relapse or progression, as evaluated according to EBMT criteria. Comparison of TTP between treatment arms is performed using the log-rank test; distributions are estimated using Kaplan-Meier methodology.

Measure: Time To Progression (TTP)

Time: Average time period between the start day of either TD or VTD as induction therapy and the day of relapse or progression

Description: PFS is defined as time from start of treatment to progression/relapse, or death, whichever occurs firstly. Comparison of PFS between treatment arms is performed using the log-rank test; distributions are estimated using Kaplan-Meier methodology.

Measure: Progression-Free Survival (PFS)

Time: Average time period between the start day of either TD or VTD as induction therapy and the day of relapse or progression or death, whichever occurs firstly

Description: OS is defined as time from start of treatment to death. Comparison of OS between treatment arms is performed using the log-rank test; distributions are estimated using Kaplan-Meier methodology.

Measure: Overall Survival (OS)

Time: Average time period between the start day of either TD or VTD as induction therapy and the day of death, due to any cause

Description: Safety is monitored until 30 days after the last dose of study drug. Toxicities are graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 3.0. Rates of adverse events are compared between treatment arms using the chi-square test.

Measure: Safety

Time: Average time period between the start day of either TD or VTD as induction therapy and the day of any toxicity/adverse event(s) recorded during and after study drug administration


HPO Nodes


Thromboembolism
Genes 17
HABP2 ADA2 F2 CBS FCGR2C SERPINC1 INHBA MTHFR PRKAR1A HRG KCNQ1 MMACHC JAK2 F13A1 EPOR PRDX1 PIGA
Amyloidosis
Genes 30
LIG4 TNFRSF1A APOA1 NLRP1 SLC7A7 CST3 MEFV GSN SAA1 OSMR PSEN2 TTR B2M RET ITM2B MEFV NLRP3 NLRP3 IL31RA LYZ ITM2B CCND1 APP PRNP POLA1 CST3 APP APOE FGA NLRP3
Deep venous thrombosis
Genes 17
PROC HABP2 F5 SERPINC1 PMM2 F2 AKT1 SERPIND1 SERPINC1 PIEZO1 PROS1 MTHFR PROC THBD F13A1 PLAT F9
Pulmonary embolism
Genes 57
GDF2 MPL TLR4 COX1 SERPINC1 AKT1 STAT4 CCR1 PROS1 CBS TRNF TET2 TRNH GNAQ ND1 ACVRL1 ND4 SERPINC1 GNAQ F2 TRNW COX3 PROS1 ERAP1 AGGF1 TRNL1 PROC F13A1 KLRC4 IL10 PROS1 UBAC2 HLA-B PIGA PROC COX2 HABP2 TRNQ CD55 C4A SMAD4 IL12A-AS1 IL12A TRNS2 IL23R KCNJ5 ND6 MEFV TRNS1 PTEN ND5 MTHFR PROC FAS PLP1 ENG JAK2
Multiple myeloma
Genes 3
LIG4 CCND1 GBA
Atherosclerosis
Genes 88
SMPD1 LDLRAP1 LDLR ACTA2 CYP7A1 ANTXR1 GLB1 FBN1 APOE APOB MAT2A ABCG8 ZNF687 LMNA AGPAT2 NPC1 LMNA GGCX FOS GGCX AGXT LMNA FOXE3 CAVIN1 SERPIND1 SMAD4 TGFBR2 SMPD1 APOB SMAD3 MYH11 CAV1 LMNA ACTA2 ABCG8 TNXB CYP27A1 COL3A1 ZMPSTE24 TGFB3 PRKG1 MYLK CEP19 LMNA ALMS1 LDLRAP1 CSF2RA APOA5 NOTCH3 ESR1 LCAT ABCA1 KCNJ5 MYH11 CSF2RB ENG TGFBR3 TGFB2 SC5D ABCC6 WRN ENPP1 HGD ANGPTL6 ELN XYLT2 LMNA ABCA1 BSCL2 LIPC PPARG SMPD1 LMNA LCAT MFAP5 ABCA1 BANF1 LMNA LOX MYH11 ABCC6 PPARG LOX XYLT1 PCSK9 NPC2 TGFBR1 ABCG5